Wellington Management Group LLP Acquires 55,617 Shares of argenx SE (NASDAQ:ARGX)

Wellington Management Group LLP increased its stake in argenx SE (NASDAQ:ARGX - Free Report) by 13.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 482,346 shares of the company's stock after buying an additional 55,617 shares during the quarter. Wellington Management Group LLP owned approximately 0.81% of argenx worth $261,470,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. J.Safra Asset Management Corp raised its position in argenx by 590.0% during the second quarter. J.Safra Asset Management Corp now owns 69 shares of the company's stock worth $30,000 after acquiring an additional 59 shares in the last quarter. Blue Trust Inc. raised its holdings in shares of argenx by 620.0% in the 2nd quarter. Blue Trust Inc. now owns 72 shares of the company's stock valued at $28,000 after purchasing an additional 62 shares during the period. GAMMA Investing LLC lifted its stake in argenx by 51.3% in the 2nd quarter. GAMMA Investing LLC now owns 118 shares of the company's stock valued at $51,000 after purchasing an additional 40 shares during the last quarter. Cromwell Holdings LLC grew its holdings in argenx by 73.3% during the third quarter. Cromwell Holdings LLC now owns 156 shares of the company's stock worth $85,000 after purchasing an additional 66 shares during the period. Finally, Point72 Hong Kong Ltd bought a new position in argenx during the second quarter worth about $76,000. Institutional investors and hedge funds own 60.32% of the company's stock.

argenx Price Performance

ARGX traded down $3.01 on Friday, hitting $623.11. 155,011 shares of the stock were exchanged, compared to its average volume of 308,561. argenx SE has a 12 month low of $327.73 and a 12 month high of $630.00. The firm has a market capitalization of $37.62 billion, a price-to-earnings ratio of -708.08 and a beta of 0.59. The business has a 50-day moving average of $574.53 and a two-hundred day moving average of $506.04.

argenx (NASDAQ:ARGX - Get Free Report) last issued its quarterly earnings results on Thursday, October 31st. The company reported $1.39 earnings per share for the quarter, topping analysts' consensus estimates of $0.10 by $1.29. The company had revenue of $588.88 million during the quarter, compared to the consensus estimate of $543.29 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. During the same quarter in the prior year, the firm posted ($1.25) EPS. Equities research analysts expect that argenx SE will post 2.2 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently issued reports on ARGX shares. Wedbush reaffirmed an "outperform" rating and issued a $655.00 price objective on shares of argenx in a research report on Tuesday, December 3rd. Citigroup raised their price target on argenx from $512.00 to $635.00 and gave the company a "buy" rating in a report on Thursday, October 17th. Oppenheimer reiterated an "outperform" rating and issued a $675.00 price objective (up from $646.00) on shares of argenx in a report on Thursday, November 21st. Wolfe Research raised shares of argenx from a "peer perform" rating to an "outperform" rating and set a $697.00 target price for the company in a report on Tuesday, November 12th. Finally, Deutsche Bank Aktiengesellschaft lowered shares of argenx from a "buy" rating to a "hold" rating in a research note on Friday, October 4th. Three research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, argenx currently has an average rating of "Moderate Buy" and a consensus price target of $635.42.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.